BMI Class
BMI Class (> 29 Kg/m 2 , n=9) M/F 12/6 6/3 6/3 Age (yrs) 60 ± 7 62.6 ± 5.9 58 ± 7.7 Weight (Kg) 79 ± 9.5 72.5 ± 8.0 85.7 ± 5.4 BMI (kg/m 2 ) 29.1 ± 3.2 26.6 ± 1.8 31.7 ± 2.0 Known DM duration (yrs) 12.8 ± 7.5 12.8 ± 9.5 12.8 ± 5.4 A1C (%) 7.5 ± 0.6 7.5 ± 0.7 7.6 ± 0.7 Fasting C-peptide (ng/ml) 1.54 ± 0.91 1.1 ± 0.6 1.7 ± 1.3 Treatments insulin ± OHA § insulin ± OHA † insulin ± OHA † Insulin dose (U/kg/day)* total 0.64 ± 0.42 basal 0.34 ± 0.17 total 0.5 ± 0.4 basal 0.3 ± 0.1 total 0.7 ± 0.5 basal 0.4 ± 0.2 Data are means ± SD.
§ All 18 subjects on basal insulin (NPH), 13 on basal-bolus; 9 subjects were also on metformin (5 on basal-bolus, 3 basal insulin only, 1 basal insulin only + repaglinide; 1 subject on basal insulin only + repaglinide). *Prandial: rapid-acting insulin analogue; basal: NPH insulin.
† In the group with BMI<29 Kg/m 2 four subjects were using metformin and one subject was using repaglinide. In the group with BMI>29 Kg/m 2 five subjects were using metformin and one subject was using repaglinide. In all subjects the last administration of oral antidiabetic drug was the day before of the euglycemic clamp study.
Supplementary Table 2.
The table reports a model to predict mean GIR infusion during euglycemic clamps, in the 18 subjects studied, following administration of the long-acting insulin analogues based on age, BMI, C-peptide concentrations and diabetes duration. The final model has an R 2 of 0.57 (adjusted R 2 of 0.45), the F value for the test of the ovearall goodness of fit was 4.44 with 4 numerator and 13 denominator degrees of freedom, which is associated with p<0.05 (0.017), power (5%) =0.81 Supplementary Table 4 . Correlations between minimal duration of action, duration of action and end of study with BMI with insulin NPH, Detemir and Glargine in the 18 subjects studied during euglycemic clamps. BMI resulted to be inversely correlated with the duration of action. However, the correlation was significant only with the minimal duration of action with NPH and detemir but not for glargine. Duration of action was defined as the minimal duration of action (MDA § )and duration of action (DA † ) (calculated as the time at which plasma glucose was 118 and 136 mg/dL, respectively). The study ended (ES ‡ ) at the time at which plasma glucose was, for at least 30 min, greater than 150 mg/dL (all definitions in the absence of glucose infusion).
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